Impavido Capsules is an FDA-approved treatment for cutaneous, mucosal, and visceral leishmaniasis in patients 12 years of age and older. The capsules contain the active ingredient miltefosine, an antileishmanial agent, and are indicated for the treatment of various forms of leishmaniasis caused by specific Leishmania species. Impavido is known for its efficacy in treating these infections, although its effectiveness may vary depending on the patient's weight. It is important for pregnant women to avoid taking Impavido due to the potential risks it poses to the fetus.
Impavido Capsules are available at various medical centers and hospitals across the United States, including Cook Children's Medical Center, Johns Hopkins All Children's Hospital, and Texas Children's Hospital, among others. The capsules are administered orally for a specific duration depending on the type of leishmaniasis being treated. Patients who weigh 99 lbs or more may require a different dosage compared to those with lower weights. It is recommended for higher-weight patients and pregnant women exposed to Impavido to enroll in the respective registries to monitor any potential risks or side effects.
Generated from the website